Many US public schools in 'air pollution da...(and maintaining existing ones. The ...)
Navigation Links
Many US public schools in 'air pollution danger zone'
Date:8/18/2008
and maintaining existing ones."
The state of California, for example, has passed a law prohibiting the building of new schools within 500 feet (168 meters) of a busy road. New Jersey is moving a bill through the legislature to require highway entrance and exit ramps to be at least 1,000 feet from schools.
'/>"/>
| Contact: Amanda Harper amanda.harper@uc.edu 513-558-4657 University of Cincinnati Source:Eurekalert |
Related biology news :
1. New book tutors future presidents and public on science behind the headlines
2. New publication addresses safety of imported foods
3. Study shows increased education on nanotech, human enhancement increases public concerns
4. NASA scientist James Hansen to speak at July 11 conference on Rejuvenating Public Sector Science
5. Queens University launches UKs first Center of Excellence for Public Health
6. Saving face with a baby-face? Shape of CEOs face affects public perception
7. BIO-key(R) Showcasing Public Safety Solutions for BlackBerry Smartphones at 2008 LEIM Conference
8. Not just for the monkeys: New publication shows evolution is everywhere
9. Publication offers labs consensus recommendations for diagnosing parasitic diseases
10. Scientists to explore global change-public health connection
11. Study finds health professionals, public unprepared for genomic medicine
Post Your Comments:
Breaking Biology News(10 mins):Delivering medicine directly into a tumor 2Genome BC collaborates with Chile and Norway to sequence salmon genome 2Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results 51826 1ResMed Announces Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year End 2009 Results 51826 2ParagonRx Files with FDA REMS Panel Interim Analysis for Opioid Drugs Study 13051 1CorVel Announces Earnings Release Webcast 51821 1CorVel Announces Earnings Release Webcast 51821 2
Other Biology News:Supercomputer provides massive computational boost to biomedical research at TGen 2Supercomputer provides massive computational boost to biomedical research at TGen 3Nutrition and bone health session to open the IOF World Congress on Osteoporosis in Bangkok 2Stanford researchers: Global warming is killing frogs and salamanders in Yellowstone Park 2Stanford researchers: Global warming is killing frogs and salamanders in Yellowstone Park 3
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 2ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 3ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis 4AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3
[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology[0] ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia[0] Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures
Other Biology Technology:Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 2Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 3Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 4Fujitsu PalmSecure and HT Systems' PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft 5Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 2AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM) 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |